GÖTTINGEN (dpa-AFX) – According to its own statements, the laboratory supplier Sartorius (Sartorius vz) is making faster progress with its growth plans. The Dax (DAX 40) group is currently about two years ahead of its own plan, said company boss Joachim Kreuzburg of the German Press Agency. 2022 was the third year of an intensive growth phase, said Kreuzburg. “It was a very successful phase.”
After a strong increase in 2020 and 2021, double-digit growth was again achieved in 2022. Compared to the two previous years, in which sales were also boosted by the pandemic, a “normalization” can be felt. Customers are hoarding less inventory because supply chain problems have decreased.
In 2019, Sartorius set a target of five billion euros in sales by 2025. “But our targets for 2025 remain basically unchanged because the market fundamentals have not changed,” said Kreuzburg. After all, the number of patients and the drugs they need will probably not change in the coming years.
In September 2021, the company was promoted to the leading German stock exchange index as part of the Dax restructuring. This has changed little for the company, said Kreuzburg. The rise made the company a little more prominent. That is something positive in times of labor shortages./xma/DP/jha
Leverage must be between 2 and 20
No data